Creative Biolabs provides comprehensive drug development services to customers around the world. With many years of research experience in immunology, we actively promote antibody development to provide you with comprehensive support in the development of drugs for Sjogren's syndrome (SS).
SS is the second most common multisystem autoimmune disease after rheumatoid arthritis. It is characterized by eye and mouth dryness and lymphocytic infiltration of the salivary glands. In addition to dryness, the clinical presentation of SS generally includes asthenia and arthralgia. The disease can extend beyond the exocrine glands, and systemic manifestations including vasculitis, lung, renal or neurological involvement can occur. Patients with SS also have an increased risk of lymphoma.
Total glucosides of peony (TGP) may be a beneficial treatment for primary Sjogren's syndrome (pSS). In one study, scientists observed that EULAR sojgren's syndrome patient reported Index (ESSPRI) of the TGP group had significantly improved not only at week 24, but also at each follow-up compared with those of the placebo group in this 24-week study. Furthermore, eye dryness symptoms of the TGP group were significantly improved at all follow-up points. Moreover, throat dryness symptoms lightened at weeks 4 and 8. Mouth and skin dryness symptoms also tended to improve.
There is an FDA-approved genetically engineered human/mouse chimeric monoclonal antibody that is specific for the CD20 antigen on the surface of B cells. This antibody demonstrated a clear effect on parotidomegaly and systemic manifestations of patients with SS, such as vasculitis, arthritis, renal and lung disease. The efficacy of this antibody on articular involvement was also confirmed using the 28-joint disease activity score (DAS-28). Recently an additional randomized trial, which included a small number of patients without systemic manifestations, has shown a significant decrease in fatigue in patients treated with this antibody.
B lymphocytes were indicated as one of the targets for an optimal therapeutic approach for pSS. B-lymphocyte stimulator (Blys) seems to be a cytokine important for B-cell survival and maturation, and then to have a major role in pathogenesis by regulating B-cell activation and autoantibody production in pSS. We provide antibody development services for B-lymphocyte stimulator (BLys).
Based on our rich experience in immunotherapy, Creative Biolabs provides our customers with high-quality antibody and cell therapy services for SS drug development. We have multiple testing platforms to evaluate the quality of antibodies in all-around aspects to provide you with the highest quality antibodies. Our standardized operating procedures help us win the trust of customers. You can participate in our services throughout the entire process, at the same time, we will help you tailor the most suitable service according to your advice. Giving yourself a chance to try our professional services that including but not limited to:
With many years of experience in drug development, Creative Biolabs provides the most reliable service for our customers worldwide. We are confident to provide you with satisfactory service. If you are interested in our services, please contact us.
Reference
For Research Use Only | Not For Clinical Use
Contact us
USA
Creative Biolabs is a world-leading CRO that is skilled in developing novel therapies,
especially in antibody and cell therapy for autoimmune diseases.
Copyright © 2024 Creative Biolabs. All Rights Reserved.
